Helixmith Recommends Park Young-joo, Head of US Branch, as Inside Director

Agenda for the Regular General Meeting on the 31st Confirmed

Park Young-joo, Head of Clinical Development Division and President of the U.S. Branch at Helixmith.

[Asia Economy Reporter Lee Gwan-joo] Helixmith announced on the 11th that it recommends Park Young-joo, head of clinical development and head of the U.S. branch, as a new inside director candidate.

After obtaining a master's and doctoral degree in statistical epidemiology from the Graduate School of Public Health at Seoul National University, Park has continuously worked in the pharmaceutical and bio industries, building experience in the field of clinical trials.

From 1996, for 20 years, Park gained extensive experience in clinical trial planning, data management, biostatistics, safety management, MW (Medical Writing), and global clinical management at global pharmaceutical companies MSD and Sanofi. He also served as the head of the Korean branch of the global R&D organization for over 10 years, overseeing personnel, budget planning and execution, and organizational management. Since joining Helixmith in 2020, he has demonstrated his capabilities by leading clinical trials in the U.S., according to the company.

Helixmith CEO Yoo Seung-shin said, “Park has been involved in clinical development at global pharmaceutical companies and venture firms for over 20 years, and he possesses excellent insight into planning, executing, and managing related budgets. We believe he will play a very significant role as an inside director.” He added, “With the number of female executives increasing to two, we will establish a management system that leads the bio industry in line with global ESG trends.”

Helixmith’s board of inside directors previously consisted of five members, including CEO Kim Sun-young, CEO Yoo Seung-shin, and Director Seo Je-hee. However, Director Seo’s term expires at this shareholders’ meeting, allowing for the appointment of one inside director. The outside directors, composed of Professor Charles Buntra of Oxford University and former Fair Trade Commission Chairman Noh Dae-rae among three members, remain unchanged. Helixmith’s regular shareholders’ meeting will be held on the 31st of this month.

This content was produced with the assistance of AI translation services.